ALX Oncology Doses First Patient in Phase 2 ASPEN-09 Breast Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
ALX Oncology announced that the first patient has been dosed in the Company's Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept with trastuzumab and physicians' choice of chemotherapy in patients with HER2-positive metastatic breast cancer whose disease has progressed after ENHERTU.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALX Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
- Conference Participation: ALX Oncology will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its latest advancements in cancer treatment, which is expected to attract investor and industry attention.
- Leadership Introduction: CEO Jason Lettmann and CMO Barbara Klencke will jointly attend to share the company's strategic developments in novel therapy, aiming to enhance market confidence and attract potential investments.
- Live Webcast: The presentation will be live-streamed via the Investors section of ALX Oncology's website, providing convenient access to a broader audience to stay updated on the company's latest developments.
- Therapeutic Progress: ALX Oncology's lead candidate, evorpacept, is currently being evaluated in multiple clinical trials, demonstrating potential in immuno-oncology, which may lay the foundation for future cancer therapies.
Continue Reading
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
Continue Reading